Alpha Teknova, Inc. (TKNO)
| Market Cap | 214.44M -35.1% |
| Revenue (ttm) | 41.80M +9.3% |
| Net Income | -17.17M |
| EPS | -0.32 |
| Shares Out | 53.61M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 269,582 |
| Open | 3.710 |
| Previous Close | 3.640 |
| Day's Range | 3.612 - 4.480 |
| 52-Week Range | 1.910 - 7.480 |
| Beta | 0.47 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 6, 2026 |
About TKNO
Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company’ primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and dr... [Read more]
Financial Performance
In 2025, Alpha Teknova's revenue was $40.52 million, an increase of 7.35% compared to the previous year's $37.75 million. Losses were -$17.26 million, -35.47% less than in 2024.
Financial StatementsNews
Alpha Teknova reports Q1 EPS (8c) vs. (9c) last year
Reports Q1 revenue $11.08M, consensus $10.22M. “We had a great start to 2026,” said Stephen Gunstream, President and Chief Executive Officer at Teknova. “The substantial investments we’ve made since 2...
Alpha Teknova backs FY26 revenue view $42M-$44M, consensus $43.01M
Matt Lowell, Teknova’s Chief Financial Officer, added, “We delivered strong financial results in the first quarter 2026 compared to 2025, including 13% revenue growth and significant improvements in A...
Alpha Teknova Earnings Call Transcript: Q1 2026
Q1 2026 saw 13% revenue growth, led by an 85% surge in Clinical Solutions and improved gross margin. Investments in commercial capabilities and automation are expected to drive double-digit growth in 2027, with positive adjusted EBITDA targeted by year-end 2027.
Teknova Reports First Quarter 2026 Financial Results
First quarter 2026 total revenue was $11.1 million, up 13% over the same quarter prior year Company reaffirms 2026 revenue guidance of $42-44 million
Teknova to Report First Quarter 2026 Financial Results on May 6, 2026
HOLLISTER, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of n...
Alpha Teknova Transcript: Sidoti March Small-Cap Virtual Conference
Revenue reached $40.5 million in 2025 with strong growth in both catalog and custom GMP products. Investments in sales, marketing, and technology, along with a new GMP facility, position the business for profitability by 2027. Clinical Solutions and Lab Essentials segments drive future upside as therapies advance through clinical stages.
Alpha Teknova Earnings Call Transcript: Q4 2025
Revenue grew 7% in 2025 with improved gross margins and reduced losses. Investments in commercial capabilities and a recovering biotech market are expected to drive future growth, with positive adjusted EBITDA targeted by end of 2027.
Alpha Teknova reports Q4 EPS (9c) vs. (11c) last year
Reports Q4 revenue $9.98M, consensus $9.61M. “After another successful year of disciplined execution against our strategic objectives, we’ve decided to further invest in our commercial capabilities th...
Alpha Teknova sees FY26 revenue $42M-$44M, consensus $44.12M
The company said, “Teknova anticipates total revenue of $42 million to $44 million for the fiscal year ending December 31, 2026. The Company also anticipates Free Cash Outflow of less
Teknova Reports Fourth Quarter and Full Year 2025 Financial Results
Full year 2025 total revenue was $40.5 million, up 7% year-over-year and in line with guidance Fourth quarter 2025 total revenue was $10.0 million, up 8% over the same quarter prior year Company provi...
Teknova to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
HOLLISTER, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of no...
Alpha Teknova Earnings Call Transcript: Q3 2025
Q3 2025 saw 9% revenue growth and improved gross margins, led by strong Lab Essentials sales, while Clinical Solutions revenue declined. The outlook remains cautious for biopharma custom products, but double-digit growth continues in other segments. Guidance for 2025 revenue is $39–$42 million, with no need for additional capital.
Alpha Teknova backs FY25 revenue view $39M-$42M, consensus $40.61M
The company said, “Teknova reiterates its fiscal 2025 outlook for revenue and Free Cash Outflow. The Company continues to anticipate total revenue of $39 million to $42 million for the
Alpha Teknova reports Q3 EPS (8c), consensus (9c)
Reports Q3 revenue $10.45M, consensus $10.23M. “We had a strong third quarter, our fifth consecutive quarter of year-over-year revenue growth, despite a very challenging funding backdrop for small- to...
Teknova Reports Third Quarter 2025 Financial Results
Third quarter 2025 total revenue was $10.5 million, up 9% from prior year Achieves five consecutive quarters of year-over-year revenue growth Company reaffirms 2025 revenue guidance of $39-42 million
Teknova to Report Third Quarter 2025 Financial Results on November 6, 2025
HOLLISTER, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of no...
Alpha Teknova Earnings Call Transcript: Q2 2025
Q2 2025 saw 7% revenue growth, strong catalog sales, and improved gross margin to 38.7%. Clinical Solutions revenue rose 32% YoY, while guidance for 2025 was reiterated at $39–$42 million. Operational efficiencies and a growing customer base support long-term growth.
Teknova Reports Second Quarter 2025 Financial Results
Second quarter 2025 total revenue was $10.3 million, up 7% from prior year Achieves four consecutive quarters of year-over-year revenue growth Company reaffirms 2025 revenue guidance of $39-42 million...
Teknova to Report Second Quarter 2025 Financial Results on August 7, 2025
HOLLISTER, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of no...
Alpha Teknova resumed with an Overweight at Stephens
Stephens resumed coverage of Alpha Teknova (TKNO) with an Overweight rating and $8 price target The company will benefit from growth in the biologics end market, the analyst tells investors
Alpha Teknova files $225M mixed securities shelf
16:35 EDT Alpha Teknova (TKNO) files $225M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stoc...
Alpha Teknova Transcript: Sidoti May Micro-Cap Virtual Conference
Custom and catalog reagent provider leverages recent infrastructure investments to scale rapidly, targeting 20%-25% growth and higher margins. Strong customer retention, fast turnaround, and new partnerships position the business for long-term profitability and expansion.
Alpha Teknova Earnings Call Transcript: Q1 2025
Q1 2025 revenue grew 5% year-over-year to $9.8M, with strong catalog product growth and improved gross margin. Guidance for 2025 was reiterated, expecting 7% revenue growth and continued margin improvement, while a new collaboration with Pluristyx expands the product portfolio.
Teknova Reports First Quarter 2025 Financial Results
First quarter 2025 total revenue was $9.8 million, up 5% from prior year Company introduced proprietary PluriFreeze™ cryopreservation system, in collaboration with Pluristyx, Inc. Company reaffirms 2...
Teknova to Report First Quarter 2025 Financial Results on May 8, 2025
HOLLISTER, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of n...